WO2012009406A3 - Particules d'or et leurs procédés de fabrication et d'utilisation dans le traitement du cancer - Google Patents

Particules d'or et leurs procédés de fabrication et d'utilisation dans le traitement du cancer Download PDF

Info

Publication number
WO2012009406A3
WO2012009406A3 PCT/US2011/043808 US2011043808W WO2012009406A3 WO 2012009406 A3 WO2012009406 A3 WO 2012009406A3 US 2011043808 W US2011043808 W US 2011043808W WO 2012009406 A3 WO2012009406 A3 WO 2012009406A3
Authority
WO
WIPO (PCT)
Prior art keywords
gold particles
making
methods
cancer treatment
same
Prior art date
Application number
PCT/US2011/043808
Other languages
English (en)
Other versions
WO2012009406A2 (fr
Inventor
Hamid Ghandehari
Adam Gormley
Adhijit Ray
Nate Larson
Original Assignee
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Utah Research Foundation filed Critical University Of Utah Research Foundation
Priority to US13/809,595 priority Critical patent/US20130177523A1/en
Publication of WO2012009406A2 publication Critical patent/WO2012009406A2/fr
Publication of WO2012009406A3 publication Critical patent/WO2012009406A3/fr
Priority to US14/461,888 priority patent/US20140358116A1/en
Priority to US14/996,419 priority patent/US20160129111A1/en
Priority to US15/634,281 priority patent/US20170290915A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2913—Rod, strand, filament or fiber
    • Y10T428/298—Physical dimension
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des particules d'or qui peuvent être utilisées pour réduire la prolifération d'une tumeur et traiter un cancer. Sous certains aspects, les particules d'or peuvent être modifiées de façon à améliorer la sélectivité et l'absorption des particules par des cellules cancéreuses. Sous certains aspects, les particules d'or modifiées ont un groupe de ciblage fixé à la particule par l'intermédiaire d'un lieur. Les particules d'or décrites par les présentes peuvent être utilisées en combinaison avec d'autres agents anticancéreux de façon à améliorer un traitement de cancer global. L'invention porte également sur des procédés de fabrication et d'utilisation des particules d'or.
PCT/US2011/043808 2010-07-13 2011-07-13 Particules d'or et leurs procédés de fabrication et d'utilisation dans le traitement du cancer WO2012009406A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/809,595 US20130177523A1 (en) 2010-07-13 2011-07-13 Gold particles and methods of making and using the same in cancer treatment
US14/461,888 US20140358116A1 (en) 2010-07-13 2014-08-18 Methods for delivering an anti-cancer agent to a tumor
US14/996,419 US20160129111A1 (en) 2010-07-13 2016-01-15 Methods for delivering an anti-cancer agent to a tumor
US15/634,281 US20170290915A1 (en) 2010-07-13 2017-06-27 Methods for delivering an anti-cancer agent to a tumor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36387510P 2010-07-13 2010-07-13
US61/363,875 2010-07-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US36387510P Continuation 2010-07-13 2010-07-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/809,595 A-371-Of-International US20130177523A1 (en) 2010-07-13 2011-07-13 Gold particles and methods of making and using the same in cancer treatment
US14/461,888 Division US20140358116A1 (en) 2010-07-13 2014-08-18 Methods for delivering an anti-cancer agent to a tumor

Publications (2)

Publication Number Publication Date
WO2012009406A2 WO2012009406A2 (fr) 2012-01-19
WO2012009406A3 true WO2012009406A3 (fr) 2012-04-12

Family

ID=45470044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/043808 WO2012009406A2 (fr) 2010-07-13 2011-07-13 Particules d'or et leurs procédés de fabrication et d'utilisation dans le traitement du cancer

Country Status (2)

Country Link
US (4) US20130177523A1 (fr)
WO (1) WO2012009406A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111228507B (zh) * 2020-03-06 2021-01-08 郑州大学 一种hpma聚合物修饰的金纳米棒载药系统及其制备方法和应用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10292956B2 (en) 2009-09-01 2019-05-21 Serbig Pharmaceutics Corp. Cancer starvation therapy
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (fr) 2010-10-01 2018-06-27 ModernaTX, Inc. Synthèse d'acides nucléiques et méthodes d'utilisation associées
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243947A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
EP2971010B1 (fr) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015034928A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides chimériques
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2015038649A1 (fr) * 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Thérapeutique ciblée
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
CN103604926B (zh) * 2013-11-27 2015-03-18 云南师范大学 一种免疫层析试纸条检测微囊藻毒素-lr的方法
EP2886128A1 (fr) * 2013-12-20 2015-06-24 Nanobiotix Compositions pharmaceutiques comportant des nanoparticules, leur préparation et leur utilisation
CN103751797B (zh) * 2013-12-30 2015-08-19 浙江工业大学 一种具有双重疗效的酶触释药制剂、其制备方法及应用
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US20160067358A1 (en) * 2014-09-05 2016-03-10 The University Of North Carolina At Charlotte Tumor specific anitbody conjugates and uses therefor
JP2018516256A (ja) 2015-05-28 2018-06-21 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 治療用ワクチンとしての使用のためのナノ粒子
US10786569B2 (en) * 2015-07-31 2020-09-29 Wei Wu Lithographically defined nanoparticles for microwave absorption
AR106073A1 (es) * 2015-09-21 2017-12-06 Serrano-Ojeda Pedro Anastacio Compuestos con glutamina y elementos con alto número atómico (z) para tratar el cáncer
CN105396134B (zh) * 2015-12-10 2018-09-11 上海交通大学 聚乙二醇-接枝-聚半胱氨酸/金复合纳米粒子、制备及应用
CN105906692A (zh) * 2016-03-11 2016-08-31 李书鹏 cRGD-厄洛替尼缀合物及其制备方法
WO2017180991A1 (fr) * 2016-04-14 2017-10-19 Board Of Trustees Of The University Of Arkansas Support de greffe à activité plasmonique, et ses procédés de fabrication et d'utilisation
US10406336B2 (en) 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
US11045548B2 (en) * 2017-07-07 2021-06-29 Georgia Tech Research Corporation Methods for inhibiting cancer cell migration with gold nanomaterials and photothermal therapy
CN109776788B (zh) * 2017-11-14 2021-07-30 博瑞生物医药（苏州）股份有限公司 叶酸受体靶向多臂偶联物
WO2020086014A1 (fr) * 2018-10-25 2020-04-30 Yeditepe Universitesi Utilisation de nanoparticules de borate de plomb ciblées par un gène p53 mutant dans le traitement du cancer et procédé de production de ces nanoparticules
US11931428B2 (en) 2019-08-23 2024-03-19 Wake Forest University Health Sciences Selective hydrogen sulfide probe and uses thereof
CN116060632B (zh) * 2023-03-29 2023-06-02 成都中医药大学 一种铋基纳米材料及其制备方法和在制备光热转导剂中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175540A1 (en) * 2003-01-25 2005-08-11 Oraevsky Alexander A. High contrast optoacoustical imaging using nonoparticles
US20090060839A1 (en) * 2007-08-22 2009-03-05 Boyes Stephen G Gold Nanoparticle Conjugates and Uses Thereof
US20110077581A1 (en) * 2009-09-25 2011-03-31 Georgia Tech Research Corporation Targeted cellular delivery of nanoparticles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175540A1 (en) * 2003-01-25 2005-08-11 Oraevsky Alexander A. High contrast optoacoustical imaging using nonoparticles
US20090060839A1 (en) * 2007-08-22 2009-03-05 Boyes Stephen G Gold Nanoparticle Conjugates and Uses Thereof
US20110077581A1 (en) * 2009-09-25 2011-03-31 Georgia Tech Research Corporation Targeted cellular delivery of nanoparticles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111228507B (zh) * 2020-03-06 2021-01-08 郑州大学 一种hpma聚合物修饰的金纳米棒载药系统及其制备方法和应用

Also Published As

Publication number Publication date
US20170290915A1 (en) 2017-10-12
US20130177523A1 (en) 2013-07-11
US20160129111A1 (en) 2016-05-12
US20140358116A1 (en) 2014-12-04
WO2012009406A2 (fr) 2012-01-19

Similar Documents

Publication Publication Date Title
WO2012009406A3 (fr) Particules d'or et leurs procédés de fabrication et d'utilisation dans le traitement du cancer
WO2012106281A3 (fr) Molécules trail multimodales et leurs utilisations en thérapies cellulaires
PH12015502112A1 (en) Cancer treatment using antibodies that bind cell surface grp78
JO3291B1 (ar) الأجسام المضادة لـ csf-1r
WO2012149546A3 (fr) Induction du gène trail par petite molécule par des cellules normales et tumorales en tant que thérapie anticancéreuse
MX349057B (es) Agente terapeutico que induce citotoxicidad.
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
WO2013040557A3 (fr) Lymphocytes t à arn modifié pour le traitement du cancer
MX2015003416A (es) Metodo para mejorar las inmunoterapias especificas en el tratamiento contra el cancer.
IN2012DN01920A (fr)
MY160499A (en) Anti-cd38 antibodies
MY173839A (en) Cd37-binding molecules and immunoconjugates thereof
WO2015009726A3 (fr) Utilisations médicales d'agonistes de cd38
PH12014501639A1 (en) Pharmaceutical compositions and methods
WO2012170776A3 (fr) Procédés de détermination du pronostic d'un patient pour la récurrence d'un cancer de la prostate et/ou déterminer une évolution de traitement pour un cancer de la prostate après une prostatectomie radicale
WO2012006634A3 (fr) Thérapie peptidique par antigène prostatique spécifique (psa)
WO2009095261A3 (fr) Compositions vaccinales
WO2013134407A3 (fr) Activation de procaspase 3 par polythérapie
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
NZ628433A (en) Chitosan-derived compositions
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
WO2013131089A3 (fr) Activité anticancéreuse puissante par activation d'un composé double
WO2012173677A3 (fr) Agents thérapeutiques anticancéreux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11807432

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13809595

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11807432

Country of ref document: EP

Kind code of ref document: A2